Dr. Martens’ (DOCS) Sector perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reissued their sector perform rating on shares of Dr. Martens (LON:DOCS) in a report published on Tuesday, Marketbeat.com reports.

A number of other equities analysts have also weighed in on the company. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research report on Tuesday, January 27th. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Dr. Martens presently has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Stock Performance

DOCS stock opened at GBX 66.85 on Tuesday. The stock’s 50 day simple moving average is GBX 75.04 and its 200 day simple moving average is GBX 82.74. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. Dr. Martens has a 12-month low of GBX 43.02 and a 12-month high of GBX 100.87. The stock has a market capitalization of £646.16 million, a PE ratio of 39.32, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last posted its earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, research analysts forecast that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In other Dr. Martens news, insider Robert Hanson acquired 96,000 shares of the stock in a transaction dated Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, for a total transaction of £75,840. In the last quarter, insiders have purchased 97,130 shares of company stock valued at $7,673,816. 2.81% of the stock is owned by corporate insiders.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.